EscharEx - MediWoundAlternative Names: EscharEx
Latest Information Update: 07 Feb 2017
At a glance
- Originator MediWound
- Class Enzymes; Skin disorder therapies
- Mechanism of Action Peptide hydrolase replacements
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Phase II Leg ulcer; Wounds